Interleukin-6 and its receptor: from bench to bedside

Area of Science:

• Immunology
• Molecular Biology
• Cell Signaling

Background:

• Interleukin-6 (IL-6) is a key inflammatory cytokine implicated in cancer and inflammation.
• IL-6 signaling typically involves binding to membrane-bound IL-6 receptors (IL-6R) and the gp130 co-receptor.
• Some cells lack membrane-bound IL-6R and are unresponsive to IL-6 via classical signaling.

Purpose of the Study:

• To review the mechanisms of IL-6 signaling, including classical signaling and trans-signaling.
• To highlight the role of soluble IL-6 receptor (sIL-6R) in enabling IL-6 to signal through gp130 on IL-6R-deficient cells.
• To introduce designer cytokines engineered to modulate IL-6 trans-signaling.

Main Methods:

• Review of existing literature on IL-6 signaling pathways.
• Analysis of data demonstrating the function of soluble IL-6R in trans-signaling.
• Description of the development and application of designer cytokines.

Main Results:

• IL-6 utilizes both classical signaling and trans-signaling pathways in physiological and pathophysiological contexts.
• Soluble IL-6R forms a complex with IL-6, enabling signaling in cells lacking membrane-bound IL-6R.
• Designer cytokines can specifically enhance or inhibit IL-6 trans-signaling.

Conclusions:

• IL-6 trans-signaling is a critical mechanism in various biological processes.
• Designer cytokines offer a targeted approach for therapeutic interventions.
• Targeting IL-6 trans-signaling holds promise for treating conditions like chronic inflammation, cancer, and for regenerative medicine applications.